Depletion of plasmacytoid dendritic cells
View Patent ↗The present invention relates to antibodies targeted to BDCA2 that deplete plasmacytoid dendritic cells (pDC) and methods of using the antibodies to treat disorders associated with pDC.
1. A monoclonal antibody or a fragment thereof that specifically binds to BDCA2, comprising
a heavy chain variable region comprising the three complementarity determining regions of the amino acid sequence of SEQ ID NO:2, and/or
a light chain variable region comprising the three complementarity determining regions of the amino acid sequence of SEQ ID NO:4.
2. The monoclonal antibody or a fragment thereof of claim 1 , which is a chimeric antibody or a fragment thereof.
3. The monoclonal antibody or a fragment thereof of claim 1 , which is a humanized antibody or a fragment thereof.
4. A pharmaceutical composition comprising the monoclonal antibody or a fragment thereof of claim 1 and a pharmaceutically acceptable carrier.
5. A kit comprising the monoclonal antibody or a fragment thereof of claim 1 and instructions for use.
6. The monoclonal antibody or a fragment thereof of claim 1 , comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:2, and/or a light chain variable region comprising the amino acid sequence of SEQ ID NO:4.
7. The monoclonal antibody or a fragment thereof of claim 1 , wherein the monoclonal antibody or a fragment thereof depletes pDC when administered to a subject.
8. A monoclonal antibody or a fragment thereof that specifically binds to BDCA2, comprising
a heavy chain variable region comprising the three complementarity determining regions of the amino acid sequence of SEQ ID NO:6, and/or
a light chain variable region comprising the three complementarity determining regions of the amino acid sequence of SEQ ID NO:8.
9. The monoclonal antibody or a fragment thereof of claim 8 , which is a chimeric antibody or a fragment thereof.
10. The monoclonal antibody or a fragment thereof of claim 8 , which is a humanized antibody or a fragment thereof.
11. A pharmaceutical composition comprising the monoclonal antibody or a fragment thereof of claim 8 and a pharmaceutically acceptable carrier.
12. A kit comprising the monoclonal antibody or a fragment thereof of claim 8 and instructions for use.
13. The monoclonal antibody or a fragment thereof of claim 8 , comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:6, and/or a light chain variable region comprising the amino acid sequence of SEQ ID NO:8.
14. The monoclonal antibody or a fragment thereof of claim 8 , wherein the monoclonal antibody or a fragment thereof depletes pDC when administered to a subject.